28 research outputs found
Author’s Reply to Letter to the Editor “Subcutaneous Granuloma Annulare in an Atypical Age Group in Immediate Post-Covid-19 Phase”
Recommended from our members
Radiofrequency ablation: A safe and economical modality in treatment of Brooke-Spiegler syndrome
Recommended from our members
Radiofrequency ablation: A safe and economical modality in treatment of Brooke-Spiegler syndrome
Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis
Autosomal recessive anhidrotic ectodermal dysplasia: A rare entity
We describe a case of anhidrotic ectodermal dysplasia (AED) with an autosomal recessive mode of inheritance, a very rare entity, in a 2-year-old female child of two asymptomatic, consanguineous parents. Their previous child also had a similar condition. Autosomal recessive AED (AR-AED) can have its full expression both in males and females and it is clinically indistinguishable from the x-linked recessive AED (XL-AED), which is the most common type of ectodermal dysplasia. Unlike the partially symptomatic carriers of XL-AED, the heterozygotes of AR-AED are phenotypically asymptomatic
Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis
Background: Psoralen UV-A (PUVA) is an established therapy for
psoriasis, but there is a well-documenated risk of melanoma and
nonmelanoma skin cancer. Narrow-band Ultraviolet-B (NBUVB) therapy has
a lower carcinogenic risk, has equal therapeutic potential and is
considerably safe in the long term than PUVA. Aim: The aim of present
study was to compare the efficacy and side-effects of PUVA and NBUVB in
chronic plaque psoriasis. Methods: Sixty patients of chronic plaque
psoriasis were taken up for the study and were randomly divided into
two groups of 30 each. They were well matched in terms of age, sex,
psoriasis extent and pretreatment psoriasis area severity index (PASI)
scoring. One group was treated with twice-weekly narrow-band UV-B
(TL-01) phototherapy and the other group received twice-weekly oral
8-Methoxsalen PUVA for a period of 3 months. Results: Both the groups
achieved >75% reduction in the PASI score or complete clearance at
the end of 3 months, but PUVA group patients required significantly
fewer number of treatment sessions and fewer number of days to clear
the psoriasis as compared to the NBUVB group, while the mean cumulative
clearance dose and adverse effects were significantly lower in the
NBUVB group. Conclusion: We concluded that PUVA group patients achieved
a faster clearance, but the adverse effects were significantly lower in
the NBUVB group